MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market

Most Favored Nation Drug Pricing Moves Forward, but Experts Warn Details Are Still Missing

Experts analyze how Trump's drug pricing policies, including Most Favored Nation (MFN) and tariffs, reshape pharma markets and impact patient costs and access.

MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market

Key TakeawaysMFN tariffs could reshape drug pricing and access, with potential long-term implications depending on legislative changes and voluntary agreements.DTC channels disrupt traditional pharmacy operations, raising compliance concerns and altering the dynamics of drug pricing and patient access.The 340B program's pricing dynamics are linked to MFN, affecting hospital revenues and potentially leading to service reevaluations.Policy [...]

Most Favored Nation, Direct-to-Consumer Strategies Reshape US Pharma Landscape, Challenging Traditional Care

Experts discuss the implications of the Most Favored Nation drug policy, discussing its impact on pricing, community pharmacy, and patient safety in the final part of a webinar series.